These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Johnson AP; Uttley AH; Woodford N; George RC Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434 [TBL] [Abstract][Full Text] [Related]
7. Are glycopeptides still appropriate and convenient for empiric use? Gonzalez-Ruiz A; Richardson J J Chemother; 2008 Oct; 20(5):531-41. PubMed ID: 19028614 [TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042 [TBL] [Abstract][Full Text] [Related]
9. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin. Hsiao SH; Chang CM; Tsai JC; Lin CY; Liao LH; Lin WL; Wu TJ Ann Pharmacother; 2007 May; 41(5):891-4. PubMed ID: 17426073 [TBL] [Abstract][Full Text] [Related]
10. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Lai CC; Chen CC; Chuang YC; Tang HJ Sci Rep; 2017 Jan; 7():41758. PubMed ID: 28139739 [TBL] [Abstract][Full Text] [Related]
11. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Knudsen JD; Fuursted K; Espersen F; Frimodt-Møller N Antimicrob Agents Chemother; 1997 Sep; 41(9):1910-5. PubMed ID: 9303383 [TBL] [Abstract][Full Text] [Related]
12. Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides. Chisari G Curr Clin Pharmacol; 2008 Sep; 3(3):153-5. PubMed ID: 18781901 [TBL] [Abstract][Full Text] [Related]
13. Allergic cross-reaction of teicoplanin and vancomycin. Grek V; Andrien F; Collignon J; Fillet G J Antimicrob Chemother; 1991 Sep; 28(3):476-7. PubMed ID: 1835723 [No Abstract] [Full Text] [Related]
14. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin. Marshall C; Street A; Galbraith K J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391 [TBL] [Abstract][Full Text] [Related]
15. Teicoplanin in perspective. A critical comparison with vancomycin. Janknegt R Pharm Weekbl Sci; 1991 Aug; 13(4):153-60. PubMed ID: 1834985 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. Harland S; Tebbs SE; Elliott TS J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471 [TBL] [Abstract][Full Text] [Related]
17. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549 [TBL] [Abstract][Full Text] [Related]
18. IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin. Knudsen JD; Pedersen M Scand J Infect Dis; 1992; 24(3):395-6. PubMed ID: 1380722 [TBL] [Abstract][Full Text] [Related]
19. The activity of vancomycin and teicoplanin alone and in combination with gentamicin or ampicillin against Streptococcus faecalis. Chen HY; Williams JD Eur J Clin Microbiol; 1984 Oct; 3(5):436-8. PubMed ID: 6238822 [TBL] [Abstract][Full Text] [Related]
20. Teicoplanin administration in patients experiencing reactions to vancomycin. Smith SR; Cheesbrough JS; Makris M; Davies JM J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221 [No Abstract] [Full Text] [Related] [Next] [New Search]